NCT00568906

Brief Summary

This study will help us understand the gene expression profiles of lung cancer. We will identify genes related to lung cancer development, their growth and metastasis to the lung. In addition, we will examine the role nicotine in the development and progression of lung tumors of smokers, ex-smokers, non-smokers on supplemental nicotine and non smokers with no exposure to nicotine.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
129

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Feb 2002

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2002

Completed
5.8 years until next milestone

First Submitted

Initial submission to the registry

December 4, 2007

Completed
2 days until next milestone

First Posted

Study publicly available on registry

December 6, 2007

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 30, 2010

Completed
10 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2011

Completed
Last Updated

May 2, 2019

Status Verified

April 1, 2019

Enrollment Period

8.8 years

First QC Date

December 4, 2007

Last Update Submit

April 30, 2019

Conditions

Carcinoma, Giant CellCarcinoma, Non-Small-Cell LungLung Cancer

Outcome Measures

Primary Outcomes (1)

  • identify genes related to lung cancer development, their growth and metastasis to the lung.

    day one

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients who agree to participate in this study will be those who are undergoing wedge resection, lobectomy on pneumonectomy for clinically diagnosed lung carcinoma or metastatic tumors to the lung, or who are undergoing therapeutic or diagnostic thoracentesis for malignant pleural effusion.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Stanford University School of Medicine

Stanford, California, 94305, United States

Location

Biospecimen

Retention: SAMPLES WITH DNA

Lung tissue or pleural fluid.

MeSH Terms

Conditions

Carcinoma, Giant CellCarcinoma, Non-Small-Cell LungLung Neoplasms

Condition Hierarchy (Ancestors)

CarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsCarcinoma, BronchogenicBronchial NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteLung DiseasesRespiratory Tract Diseases

Study Officials

  • Daya Upadhyay

    Stanford University

    PRINCIPAL INVESTIGATOR

  • Glenn D. Rosen

    Stanford University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 4, 2007

First Posted

December 6, 2007

Study Start

February 1, 2002

Primary Completion

November 30, 2010

Study Completion

October 1, 2011

Last Updated

May 2, 2019

Record last verified: 2019-04

Locations

US(1)